Prostate‐specific membrane antigen positron emission tomography/computed tomography imaging as a precision diagnostic at prostate cancer recurrence after radical prostatectomy: Modeling long‐term survival
Cancer · 2025
DOI: 10.1002/cncr.70131 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Kemal Caglar Gogebakan und 18 weiteren Autor:innen. Beteiligte Einrichtung: Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron Emission Tomography Computed Tomography, Neoplasm Recurrence, Local, Glutamate Carboxypeptidase II. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
Prostate‐specific membrane antigen positron emission tomography/computed tomography (PSMA‐PET/CT) is affecting the management of patients with prostate cancer with biochemical recurrence after radical prostatectomy. The long‐term outcomes of tailoring salvage treatment on the basis of PSMA‐PET/CT status remain to be determined.
Methods
A decision‐analytic model was developed to project incremental life‐years of strategies that allocate treatments at biochemical recurrence after radical prostatectomy on the basis of PSMA‐PET/CT status (PSMA‐metastatic vs. PSMA‐nonmetastatic). Modeled treatments are local/regional (radiation) or systemic (hormone therapy and doublet therapy), administered immediately or delayed. PSMA‐metastatic status was assumed to lead to treatment intensification, whereas PSMA‐nonmetastatic status would lead to deintensification. To project survival, data on progression to metastasis from a clinical cohort were combined with registry data on postmetastasis survival. Because of the lack of data on long‐term treatment benefits by PSMA status, survival was projected by varying the hazard ratio (HR) for disease‐specific death among PSMA‐metastatic versus PSMA‐nonmetastatic patients under delayed or local/regional regimens (HR1) and under immediate systemic regimens (HR2).
Results
Mean life‐years are projected to be 15.5 under the non–PSMA‐tailored strategy, and mean incremental life‐years range from 0.38 to 0.81 depending on HR1 and HR2. A greater benefit is projected when PSMA‐metastatic status is more adverse under salvage regimens that do not include systemic agents.
Conclusions
This decision‐analytic modeling study projects that PSMA‐PET/CT–guided management at biochemical recurrence after radical prostatectomy yields a modest survival benefit under the specified model inputs and assumptions regarding treatment distributions. These findings may complement emerging data on the corresponding economic costs and health‐related quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
- The Comparative Health Outcomes, Policy, and Economics Institute, University of Washington, Seattle, Washington, USA.
- Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, and Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Cologne, Germany.
- Department of Nuclear Medicine, DKTK and NCT University Hospital Essen, Essen, Germany.
- Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California, USA.
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA.
ORCID-Profile: Kemal Caglar Gogebakan, Zizi Elsisi, Lukas Owens, Roman Gulati, Sigrid Carlsson
Förderung
- NCI NIH HHS
Zitieren
APA
Gogebakan, K. C., Elsisi, Z., Montano-Campos, F., Owens, L., Zhao, Y., Gulati, R., Ferdinandus, J., Fendler, W. P., Calais, J., Hope, T. A., Carlsson, S., Fainberg, J., Laudone, V., Kunst, N., Berlin, A., Schipper, M., Barbour, A., Iravani, A., & Etzioni, R. (2025). Prostate‐specific membrane antigen positron emission tomography/computed tomography imaging as a precision diagnostic at prostate cancer recurrence after radical prostatectomy: Modeling long‐term survival. Cancer. https://doi.org/10.1002/cncr.70131
Vancouver
Gogebakan KC, Elsisi Z, Montano-Campos F, Owens L, Zhao Y, Gulati R, et al. Prostate‐specific membrane antigen positron emission tomography/computed tomography imaging as a precision diagnostic at prostate cancer recurrence after radical prostatectomy: Modeling long‐term survival. Cancer. 2025. doi:10.1002/cncr.70131
BibTeX
@article{Gogebakan2025,
author = {Gogebakan, Kemal Caglar and Elsisi, Zizi and Montano-Campos, Felipe and Owens, Lukas and Zhao, Yibai and Gulati, Roman and Ferdinandus, Justin and Fendler, Wolfgang P and Calais, Jeremie and Hope, Thomas A and Carlsson, Sigrid and Fainberg, Jonathan and Laudone, Vincent and Kunst, Natalia and Berlin, Alejandro and Schipper, Matthew and Barbour, Andrew and Iravani, Amir and Etzioni, Ruth},
title = {Prostate‐specific membrane antigen positron emission tomography/computed tomography imaging as a precision diagnostic at prostate cancer recurrence after radical prostatectomy: Modeling long‐term survival},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.70131}
}
EUVIMED